Caring for Those Who Cared for Us

FDA blood test clearance; pTau217 high accuracy; plasma p-tau studies; AI speech/handwriting; ki:elements phone speech; Dunedin pTau181; single MRI 92.8%; (MC)2 screen; driving indicators. New: misfolded proteins test; smartphone walking speed; HRV markers; NHS trial; aperiodic EEG; primary care clinician education; self-administered finger-prick p-tau217; multimodal composites; Down syndrome trials; ADNI4; pTau181 midlife signals; GFAP/tau PET; PI-2620 PSP tracking; AsymAD CgA resilience; non-memory signs; MileAge clock; handwriting dictation; sensory decline (hearing/smell 5-20yr early warning, hearing aids 33% lower risk); DLB practical diagnosis guide; ATN framework explainer; falls as preclinical AD marker; comorbidities shift p-tau217 cutoffs; reversible mimics (apathy, smell loss, RBD, word-finding, B12 deficiency). Recent reinforcement: CSF biomarker utility (59.6% management change); caregiver guide on early stages; Eisai investor day reinforces Aβ42/40 and p-tau217 centrality. New nuance: pTau181 at age 45 shows no MRI/cognitive association, questioning midlife utility; insulin resistance independent pathway adds complexity. New: psychological well-being trajectories decline before MCI/dementia diagnosis—non-invasive early warning signal. Recent: handwriting analysis as a subtle early sign (dictation task, fragmented strokes) reinforces existing non-memory cues. New: Alpha-Synuclein RT-QuIC for LBD differential diagnosis; florbetapir-PET spatial extent metric (EXT) reclassifies 21.4% of SUVR-negative cases and predicts tau/cognitive decline; multimodal deep learning framework (HuBERT + BERT with mutual information maximization) for speech-based dementia detection. New: Plasma eMTBR-tau243 combined with %p-tau217 enables biological staging without PET—major step for primary care accessibility. New: Speech pattern AI analysis (filler words, pauses) adds to vocal biomarker toolkit. New: DLB prevalence quantified (underdiagnosed, more common than ALS)—reinforces need for LBD-specific awareness. New: ALZ Talks video on Down syndrome and Alzheimer's intersection provides practical guidance for families. New: Digital cognitive screening tool (Mindmore-P) for postoperative cognitive changes; AI speech analysis predicting Alzheimer's 6 years early (78.2% accuracy) adds to vocal biomarker toolkit. New: Multilingual dementia detection (NeoBERT) shows bilingual fine-tuning eliminates cross-lingual degradation—equity in screening. New: Personal story of nurse with DLB navigating workplace disclosure and retirement—validates young-onset LBD challenges. New: Neuroinflammation and cerebral small vessel disease in MCI/early AD (in vivo markers) adds mechanistic nuance. New: Practical cognitive tests guide reinforces screening tools and urgent escalation signs for families. Recent: Dr. Bozoki video on p-tau217 blood test ethics and interpretation—important nuance for families considering direct-to-consumer tests. New: 21-protein blood panel (96% accuracy) for early Alzheimer's detection—major step beyond single-marker tests, reduces cost 88% vs PET, enables biological staging and treatment timing. (Podcast with Yuanbing Jiang) New: Plasma biomarkers field-test in memory clinic validates ATN framework in real-world setting. New: 6 early dementia signs video (memory, navigation, language, personality, judgment) with actionable next steps. New: LBD with Dr. James E. Galvin reinforces underdiagnosis and biomarker utility.